Sequent Scientific secures WHO prequalification for Albendazole API

Sequent Scientific Limited, a leading Indian pharmaceutical company, has achieved a significant milestone by securing prequalification (PQ) approval from the World Health Organization (WHO) for its Albendazole Active Pharmaceutical Ingredient (API). This achievement, made in collaboration with Mepro Pharmaceuticals Private Limited, marks a noteworthy advancement in the pharmaceutical sector and underscores the company’s commitment to high standards in drug production.

Albendazole API: A Crucial Milestone in Global Health

Albendazole is a crucial medication used to treat various parasitic infections, including tapeworms, roundworms, and hookworms. These parasitic infections are prevalent in many low- and middle-income countries, where they can lead to severe health issues and impact overall quality of life. The WHO prequalification of Sequent Scientific Limited’s Albendazole API is a testament to the company’s dedication to producing medicines that meet stringent international quality standards. This prequalification ensures that the API is effective, safe, and of high quality, making it suitable for global distribution and use.

The approval is particularly significant as it enables the distribution of Albendazole API to a broader market, helping to address the critical need for effective treatments in underserved regions. The move aligns with global health initiatives aimed at combating parasitic diseases that affect millions of people worldwide.

Mepro Pharmaceuticals and the Innovative Albendazole Chewable Formulation

In partnership with Sequent Scientific Limited, Mepro Pharmaceuticals Private Limited has developed a chewable formulation of Albendazole that has also received global approval from the WHO PQ. This formulation represents a significant innovation, as it is the first of its kind to be approved by the WHO for use in treating parasitic infections. Mepro Pharmaceuticals has leveraged its extensive experience and advanced manufacturing capabilities to develop this formulation, which is now poised to make a substantial impact on public health.

Mepro Pharmaceuticals, headquartered in Mumbai, India, has over four decades of experience in the pharmaceutical industry. The company operates four manufacturing facilities and specializes in developing niche and technically complex pharmaceutical products. This new formulation highlights Mepro’s ability to create effective and patient-friendly medication options, further enhancing its reputation in the global market.

Expert Opinion: A Milestone for Sequent Scientific Limited

Rajaram Narayanan, Managing Director and CEO of Sequent Scientific Limited, emphasized the significance of the WHO prequalification approval by stating, “The WHO prequalification approval validates our manufacturing capabilities and reinforces our dedication to providing high-quality, affordable medicines to those in need worldwide. By leveraging our extensive distribution network and strategic partnerships, the company is poised to make a meaningful impact on health outcomes on a global scale.” This endorsement not only validates Sequent Scientific Limited’s manufacturing processes but also positions the company to play a pivotal role in improving global health outcomes.

Company Background and Market Reach

Sequent Scientific Limited is a prominent player in the Indian pharmaceutical sector with a consolidated turnover of ₹13.69 billion for FY24. The company operates through seven manufacturing facilities and serves consumers in over 90 countries. This extensive reach enables Sequent Scientific Limited to effectively distribute its products worldwide, addressing critical health needs in various regions.

Mepro Pharmaceuticals, established over 40 years ago, brings a wealth of experience to its collaboration with Sequent Scientific Limited. The company has a strong presence in highly regulated markets such as the UK, EU, Canada, and Australia, where it has built a reputation for delivering high-quality healthcare products. Its four manufacturing facilities are equipped to produce a range of complex pharmaceutical products, including the newly approved Albendazole chewable formulation.

A Step Forward in Global Health

The WHO prequalification of Sequent Scientific Limited’s Albendazole API is a significant step forward in the global fight against parasitic infections. This achievement not only highlights the company’s commitment to maintaining high standards but also represents a major advancement in making effective treatments more accessible worldwide. With its extensive experience and global distribution network, Sequent Scientific Limited is well-positioned to contribute significantly to improving health outcomes on a global scale.